 | Up a level |
Evers, G., Beelen, D. W., Braess, J., Sauerland, M. C., Kolb, H. J., Reichle, A., Holler, E., Schwerdtfeger, R., Arnold, R., Scheid, C., Krug, U., Mueller-Tidow, C., Schliemann, C., Mikesch, J. -H., Lenz, G., Woermann, B. J., Hiddemann, W., Berdel, W. E. and Stelljes, M. (2018). Allogeneic hematopoietic stem cell transplantation (HSCT) beyond first complete remission (CR) in patients with acute myeloid leukemia (AML): Results from the AMLCG1999 trial. Oncol. Res. Treat., 41. S. 117 - 119. BASEL: KARGER. ISSN 2296-5262
Koenigsmann, M., Casper, J., Kahl, C., Basara, N., Sayer, H. G., Behre, G., Theurich, S., Christopeit, M., Mohren, M., Reichle, A., Metzner, B., Ganser, A., Stadler, M., Uharek, L., Balleisen, L., Hinke, A., Hinke, R. and Niederwieser, D. (2014). Risk-adapted, treosulfan-based therapy with auto- and allo-SCT for relapsed/refractory aggressive NHL: a prospective phase-II trial. Bone Marrow Transplant., 49 (3). S. 410 - 416. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365
Krug, U., Berdel, W. E., Gale, R. P., Haferlach, C., Schnittger, S., Mueller-Tidow, C., Braess, J., Spiekermann, K., Staib, P., Beelen, D., Serve, H., Schliemann, C., Stelljes, M., Balleisen, L., Maschmeyer, G., Grueneisen, A., Eimermacher, H., Giagounidis, A., Rasche, H., Hehlmann, R., Lengfelder, E., Thiel, E., Reichle, A., Aul, C., Ludwig, W-D, Kern, W., Haferlach, T., Koepcke, W., Goerlich, D., Sauerland, M. C., Heinecke, A., Woermann, B. J., Hiddemann, W. and Buechner, T. (2016). Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia. Leukemia, 30 (6). S. 1230 - 1237. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Tschanter, P., Krug, U., Fueller, M., Klein, M., Goellner, S., Rohde, C., Roellig, C., Thiede, C., Lilly, M. A., Haack, B., Koschmieder, A., Stelljes, M., Dugas, M., Koschmieder, S., Gerss, J., Butterfass-Bahloul, T., Wagner, R., Eveslage, M., Thiem, U., Krause, S. W., Kaiser, U., Kunzmann, V, Steffen, B., Noppeney, R., Herr, W., Baldus, C. D., Schmitz, N., Goetze, K., Reichle, A., Kaufmann, M., Neubauer, A., Schaefer-Eckart, K., Haenel, M., Peceny, R., Frickhofen, N., Kiehl, M., Giagounidis, A., Goerner, M., Repp, R., Link, H., Kiani, A., Naumann, R., Bruemmendorf, T. H., Serve, H., Ehninger, G., Berdel, W. E. and Mueller-Tidow, C. (2015). DNMT3A mutations in exon 23 are associated with improved survival in AML patients treated with Azacytidine plus standard chemotherapy. Oncol. Res. Treat., 38. S. 122 - 123. BASEL: KARGER. ISSN 2296-5262